放疗与肿瘤免疫

doi:10.3760/cma.j.issn.1673-422X.2016.11.014

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (11): 855-857.doi: 10.3760/cma.j.issn.1673-422X.2016.11.014

放疗与肿瘤免疫

许涛，景红霞

442000 十堰，湖北医药学院附属人民医院肿瘤中心（许涛），超声科（景红霞）

收稿日期:2016-02-04 出版日期:2016-11-08 发布日期:2016-11-02
通讯作者: 景红霞，Email: jinghongxia@sina.com E-mail:jinghongxia@sina.com
基金资助:
十堰市科学技术研究与开发项目（16Y46）

Radiotherapy and tumor immunity

Xu Tao, Jing Hongxia

Department of Oncology, People′s Hospital, Hubei University of Medicine, Shiyan 442000, China

Received:2016-02-04 Online:2016-11-08 Published:2016-11-02
Contact: Jing Hongxia E-mail:jinghongxia@sina.com
Supported by:
Science and Technology Study and Development Project of Shiyan City (16Y46)

摘要/Abstract

摘要： 肿瘤微环境中的免疫细胞和细胞因子在抗肿瘤免疫中具有不同功能。放疗可通过放射生物效应杀伤肿瘤细胞，同时还能间接改变肿瘤免疫微环境，协同产生局部或远处抗肿瘤免疫效应。放疗联合免疫治疗的动物和临床试验证实其良好的应用前景，联合治疗时具体的放射治疗模式尚需进一步研究。

关键词: 放射疗法, 免疫

Abstract: Infiltrated immune cells and cytokines in the tumor microenvironment may play different functions that appear tightly related to clinical outcomes. Radiotherapy mainly kills tumor cells through radiobiological effect, meanwhile it can indirectly change tumor immunologic microenvironment, and has a local or distant antitumor immunological effect cooperatively. Animal experiments and clinical trials of radiotherapy combined with immunotherapy display well applied prospects, but the mode of radiotherapy in combined treatment needs further research.

Key words: Radiotherapy, Immunit

许涛，景红霞. 放疗与肿瘤免疫[J]. 国际肿瘤学杂志, 2016, 43(11): 855-857.

Xu Tao, Jing Hongxia. Radiotherapy and tumor immunity[J]. Journal of International Oncology, 2016, 43(11): 855-857.

参考文献

［1］ Vatner RE, Cooper BT, VanpouilleBox C, et al. Combinations of immunotherapy and radiation in cancer therapy［J］. Front Oncol, 2014, 4: 325. DOI: 10.3389/fonc.2014.00325. ［2］ Golden EB, Formenti SC. Is tumor (R)ejection by the immune system the "5th R" of radiobiology?［J］. Oncoimmunology, 2014, 3(1): e28133. DOI: 10.4161/onci.28133. ［3］ Surace L, Lysenko V, Fontana AO, et al. Complement is a central mediator of radiotherapyinduced tumorspecific immunity and clinical response［J］. Immunity, 2015, 42(4): 767-777. DOI: 10.1016/j.immuni.2015.03.009. ［4］ Golden EB, Apetoh L. Radiotherapy and immunogenic cell death［J］. Semin Radiat Oncol, 2015, 25(1): 1117. DOI: 10.1016/j.semradonc.2014.07.005. ［5］ Gameiro SR, Jammeh ML, Wattenberg MM, et al. Radiationinduced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing［J］. Oncotarget, 2014, 5(2): 403-416. DOI: 10.18632/oncotarget.1719. ［6］ Park B, Yee C, Lee KM. The effect of radiation on the immune response to cancers［J］. Int J Mol Sci, 2014, 15(1): 927943. DOI: 10.3390/ijms15010927. ［7］ Kahn J, Tofilon PJ, Camphausen K. Preclinical models in radiation oncology［J］. Radiat Oncol, 2012, 7: 223. DOI: 10.1186/1748-717X-7-223. ［8］ Hurwitz AA, Watkins SK. Immune suppression in the tumor microenvironment: a role for dendritic cellmediated tolerization of T cells［J］. Cancer Immunol Immunother, 2012, 61(2): 289-293. DOI: 10.1007/s00262-011-1181-5. ［9］ Haikerwal SJ, Hagekyriakou J, Macmanus M, et al. Building immunity to cancer with radiation therapy［J］. Cancer Lett, 2015, 368(2): 198-208. DOI: 10.1016/j.canlet.2015.01.009. ［10］ Shahabi V, Postow MA, Tuck D, et al. Immunepriming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy［J］. Am J Clin Oncol, 2015, 38(1): 90-97. DOI: 10.1097/COC.0b013e3182868ec8. ［11］ Verbrugge I, Hagekyriakou J, Sharp LL, et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies［J］. Cancer Res, 2012, 72(13): 3163-3174. DOI: 10.1158/00085472.CAN120210. ［12］ Roses RE, Datta J, Czerniecki BJ. Radiation as immunomodulator: implications for dendritic cellbased immunotherapy［J］. Radiat Res, 2014, 182(2): 211-218. DOI: 10.1667/RR13495.1. ［13］ Simpson TR, Li F, MontalvoOrtiz W, et al. Fcdependent depletion of tumorinfiltrating regulatory T cells codefines the efficacy of antiCTLA4 therapy against melanoma［J］. J Exp Med, 2013, 210(9): 16951710. DOI: 10.1084/jem.20130579. ［14］ Wu L, Wu MO, De La Maza L, et al. Targeting the inhibitory receptor CTLA4 on T cells increased abscopal effects in murine mesothelioma model［J］. Oncotarget, 2015, 6(14): 1246812480. DOI: 10.18632/oncotarget.3487. ［15］ Ruocco MG, Pilones KA, Kawashima N, et al. Suppressing T cell motility induced by antiCTLA4 monotherapy improves antitumor effects［J］. J Clin Invest, 2012, 122(10): 37183730. DOI: 10.1172/JCI61931. ［16］ Finkelstein SE, Iclozan C, Bui MM, et al. Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of highrisk soft tissue sarcoma patients［J］. Int J Radiat Oncol Biol Phys, 2012, 82(2): 924-932. DOI: 10.1016/j.ijrobp.2010.12.068. ［17］ Slovin SF, Higano CS, Hamid O, et al. Ipilimumab (IPI) in metastatic castrateresistant prostate cancer (mCRPC): results from an openlabel, multicenter phase Ⅰ/Ⅱ study［J］. Ann Oncol, 2013, 24(7): 1813-1821. DOI: 10.1093/annonc/mdt107. ［18］ Schoenfeld JD, Mahadevan A, Floyd SR, et al. Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review［J］. J Immunother Cancer, 2015, 3: 50. DOI: 10.1186/s40425-015-0095-8. ［19］ Kamrava M, Kesarwala AH, Madan RA, et al. Longterm followup of prostate cancer patients treated with vaccine and definitive radiation therapy［J］. Prostate Cancer Prostatic Dis, 2012, 15(3): 289-295. DOI: 10.1038/pcan.2012.7. ［20］ Gandhi SJ, Minn AJ, Vonderheide RH, et al. Awakening the immune system with radiation: optimal dose and fractionation［J］. Cancer Lett, 2015, 368(2): 185-190. DOI: 10.1016/j.canlet.2015.03.024. ［21］ Bloy N, Pol J, Manic G, et al. Trial watch: radioimmunotherapy for oncological indications［J］. Oncoimmunology, 2014, 3(9): e954929. DOI: 10.4161/21624011.2014.954929. ［22］ Schaue D, Ratikan JA, Iwamoto KS, et al. Maximizing tumor immunity with fractionated radiation［J］. Int J Radiat Oncol Biol Phys, 2012, 83(4): 1306-1310. DOI: 10.1016/j.ijrobp.2011.09.049.

[1]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[2]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[3]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[4]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[5]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[6]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[7]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[8]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[9]	钟楠, 王淡瑜, 周欢欢, 刘宁, 戴纬, 刘黎琼, 郭智. CD30单抗联合PD-1抑制剂治疗复发难治性霍奇金淋巴瘤的疗效与安全性[J]. 国际肿瘤学杂志, 2024, 51(4): 245-248.
[10]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[11]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[12]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.
[13]	解淑萍, 孙亚红, 汪超. 早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[14]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[15]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.

放疗与肿瘤免疫

Radiotherapy and tumor immunity

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价